This article was originally published in Start Up
DarPharma Inc. is targeting the overlooked D1 family of dopamine receptors in its quest to develop novel therapeutics for CNS and psychiatric disorders. The company is leading with two full D1 agonists for Parkinson's disease. Waiting in the wings are D1 receptor agonists for schizophrenia and memory and cognition disorders.
You may also be interested in...
Despite the challenges of neuropsychiatric drug discovery, focused research into CNS pathways has raised hopes that R&D can be rationalized sufficiently to lower risk. A new generation of biotechs is about understanding the neural mechanism of disorders and then finding compounds that address the mechanisms.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)